Celcuity Inc. Common Stock CELC
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T03:07:17.774Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.566736542Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:57:43.943675+00:00
Celcuity Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 77.12 | 122.6% | 21.8% | 58.10 | 81.5% | 11.4% |
| 25Δ | 73.92 | 114.4% | 17.3% | 59.32 | 85.2% | 10.0% |
| 30Δ | 71.19 | 103.4% | 13.5% | 60.49 | 86.6% | 8.7% |
| 35Δ | 69.20 | 96.4% | 10.9% | 61.59 | 84.9% | 7.7% |
| 40Δ | 67.78 | 92.4% | 9.2% | 62.69 | 83.3% | 6.7% |
| 45Δ | 66.36 | 88.4% | 7.5% | 63.79 | 81.7% | 5.6% |
| 50Δ | 64.95 | 84.7% | 5.9% | 64.88 | 80.1% | 4.6% |
| 55Δ | 63.77 | 86.9% | 5.2% | 65.87 | 78.1% | 3.9% |
| 60Δ | 62.59 | 89.1% | 4.5% | 66.85 | 76.1% | 3.3% |
| 65Δ | 61.40 | 91.3% | 3.8% | 67.83 | 74.1% | 2.7% |
| 70Δ | 60.22 | 93.5% | 3.1% | 68.81 | 72.1% | 2.1% |
| 75Δ | 58.81 | 93.2% | 2.5% | 69.78 | 70.1% | 1.5% |
| 80Δ | 57.35 | 92.3% | 1.9% | 71.33 | 69.9% | 1.1% |
20Δ
- Pseudo strike
- 77.12
- IV
- 122.6%
- B/E move
- 21.8%
- Pseudo strike
- 58.10
- IV
- 81.5%
- B/E move
- 11.4%
25Δ
- Pseudo strike
- 73.92
- IV
- 114.4%
- B/E move
- 17.3%
- Pseudo strike
- 59.32
- IV
- 85.2%
- B/E move
- 10.0%
30Δ
- Pseudo strike
- 71.19
- IV
- 103.4%
- B/E move
- 13.5%
- Pseudo strike
- 60.49
- IV
- 86.6%
- B/E move
- 8.7%
35Δ
- Pseudo strike
- 69.20
- IV
- 96.4%
- B/E move
- 10.9%
- Pseudo strike
- 61.59
- IV
- 84.9%
- B/E move
- 7.7%
40Δ
- Pseudo strike
- 67.78
- IV
- 92.4%
- B/E move
- 9.2%
- Pseudo strike
- 62.69
- IV
- 83.3%
- B/E move
- 6.7%
45Δ
- Pseudo strike
- 66.36
- IV
- 88.4%
- B/E move
- 7.5%
- Pseudo strike
- 63.79
- IV
- 81.7%
- B/E move
- 5.6%
50Δ
- Pseudo strike
- 64.95
- IV
- 84.7%
- B/E move
- 5.9%
- Pseudo strike
- 64.88
- IV
- 80.1%
- B/E move
- 4.6%
55Δ
- Pseudo strike
- 63.77
- IV
- 86.9%
- B/E move
- 5.2%
- Pseudo strike
- 65.87
- IV
- 78.1%
- B/E move
- 3.9%
60Δ
- Pseudo strike
- 62.59
- IV
- 89.1%
- B/E move
- 4.5%
- Pseudo strike
- 66.85
- IV
- 76.1%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 61.40
- IV
- 91.3%
- B/E move
- 3.8%
- Pseudo strike
- 67.83
- IV
- 74.1%
- B/E move
- 2.7%
70Δ
- Pseudo strike
- 60.22
- IV
- 93.5%
- B/E move
- 3.1%
- Pseudo strike
- 68.81
- IV
- 72.1%
- B/E move
- 2.1%
75Δ
- Pseudo strike
- 58.81
- IV
- 93.2%
- B/E move
- 2.5%
- Pseudo strike
- 69.78
- IV
- 70.1%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 57.35
- IV
- 92.3%
- B/E move
- 1.9%
- Pseudo strike
- 71.33
- IV
- 69.9%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 74.68% | |
| 77.29% | |
| 77.49% | |
| 76.31% | |
| 77.08% | |
| 78.40% | |
| 78.19% | |
| 78.83% | |
| 76.30% | |
| 77.68% |
Biotechnology
CELU
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing…
More →CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in…
More →CING
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders.…
More →CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.…
More →